Summary
DexCom, Inc. (DXCM) reported a strong third quarter for 2025, demonstrating significant year-over-year growth across key financial metrics. Revenue increased by 22% to $1.21 billion, driven by a robust expansion of their customer base and continued demand for their continuous glucose monitoring (CGM) systems. This top-line growth translated into substantial improvements in profitability, with gross profit up 23% and operating income soaring by 60%. Net income more than doubled, increasing by 111% to $283.8 million, indicating enhanced operational efficiency and effective cost management. The company's financial position remains solid, with a significant increase in cash, cash equivalents, and short-term marketable securities to $3.32 billion. This robust liquidity provides DexCom with ample resources to fund ongoing operations, capital expenditures, and strategic initiatives, including ongoing product development and potential expansion into new markets. The successful launch of the Stelo biosensor and the FDA clearance for the Dexcom G7 15 Day CGM System further bolster the company's product portfolio and market reach. Despite ongoing legal proceedings and regulatory scrutiny, Dexcom has demonstrated impressive financial performance and a positive outlook for continued growth.
Financial Highlights
50 data points| Revenue | $1.21B |
| Cost of Revenue | $477.90M |
| Gross Profit | $731.40M |
| R&D Expenses | $157.50M |
| SG&A Expenses | $331.40M |
| Operating Expenses | $488.90M |
| Operating Income | $242.50M |
| Interest Expense | $3.70M |
| Net Income | $283.80M |
| EPS (Basic) | $0.73 |
| EPS (Diluted) | $0.70 |
| Shares Outstanding (Basic) | 391.10M |
| Shares Outstanding (Diluted) | 407.40M |
Key Highlights
- 1Revenue increased 22% year-over-year to $1.21 billion for the third quarter of 2025, driven by increased sales volume of disposable sensors and customer base expansion.
- 2Net income more than doubled, showing a 111% increase to $283.8 million for the third quarter, reflecting strong sales growth and operational efficiencies.
- 3Operating income surged by 60% to $242.5 million, highlighting improved profitability and cost management.
- 4The company ended the third quarter with a strong cash position of $3.32 billion in cash, cash equivalents, and short-term marketable securities.
- 5Significant investment in R&D continues, with a 16% increase in R&D expenses year-over-year, underscoring the commitment to innovation and future product development.
- 6The company experienced a substantial increase in accounts payable and accrued liabilities ($357.1 million increase), potentially indicating robust purchasing or accrual for ongoing operations and investments.
- 7DexCom received FDA clearance for the Dexcom G7 15 Day CGM System and launched its Stelo biosensor, expanding its product offerings and market reach.